RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Clinical trials for RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug trial offers hope for kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…
Matched conditions: RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…
Matched conditions: RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New drug duo tested in fight against stubborn blood cancers
Disease control OngoingThis early-phase trial is testing the safety and best dose of a two-drug combination (selinexor and choline salicylate) for adults with advanced blood cancers that have returned or stopped responding to standard treatments. The study includes patients with non-Hodgkin lymphoma, H…
Matched conditions: RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC